RAS LSS Consulting

Struggling to bring your innovation to market? The odds are steep - only 1 in 10,000 medicines make it from the lab to the market. The path is complex, with hurdles in #RandD, #RegulatoryApprovals, and #MarketDifferentiation.   At #RASLSSConsulting, we don't increase the odds of success...you do. We just operate behind the scenes, delivering #Insights that help you take bold #Decisions with confidence.   🔍 Watch our video to learn more, or reach out to see how we can help. #RASLSSConsulting - guiding you all the way, from lab to market. #RASLifeScienceSolutions #PharmaConsulting #LifeSciences #Innovation #Strategy #GetInTouch #Sevices #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #ManagementConsulting #MatchMaking #RandSupportServices #PortfolioOptimization #ConferenceCoverage #MarketEntryStrategy #PartnerIdentification

Lifera to localize over 50% of Saudi Arabia's insulin needs with Novo Nordisk Saudi Arabia! Lifera have announced an agreement with Novo Nordisk, the world's largest #producer of #insulin. Through Lifera’s subsidiary, #SaudiBio, the two companies have agreed to localize insulin production in #SaudiArabia. Saudi Arabia is set to become the first #GulfCooperationCouncil (GCC) nation to produce an #innovatorbiologicinsulin locally, by 2027. This move towards #localinsulinmanufacturing will support the diversification of Saudi Arabia's economy, contribute to the growth of the biopharmaceutical sector, and align with Saudi Vision 2030. Lifera’s mission is to enhance Saudi Arabia's resilience in biopharmaceuticals and advance the #NationalBiotechnologyStrategy, both of which are supported by localizing insulin production and developing cutting-edge biomanufacturing capabilities. Novo Nordisk Saudi Arabia emphasized that this landmark agreement would bring innovative solutions closer to people living with diabetes across the Kingdom. Moreover, will increase access to affordable medications and strengthen the national healthcare supply chain. The announcement of local insulin production marks a significant step towards sustainable access to innovative therapies in partnership with National Unified Procurement Company "NUPCO", the Local Content And Government Procurement Authority (LCGPA), and other key stakeholders committed to improving the quality of life for those with diabetes. #Lifera #NovoNordisk #NovoNordiskSaudiArabia #SaudiBio #Insulinlocalization #Partnership #GCCInsulinmanufacturing #LocalBiopharmaceuticalsproduction #SaudiVision2030 #NUPCO #LCGPA #RASLSSConsulting #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #PortfolioOptimization For detailed news: https://lnkd.in/dGP-VKRa Know more about #RASLSSConsulting: https://lnkd.in/d_daJ5Xv Follow our page for more industry updates: https://lnkd.in/de5zNWmK

A new treatment on the way for psoriasis patients! 🚀 Innovent's Picankibart Shows Promising Results in Phase 2 Trial for Psoriasis Patients Unresponsive to Previous Biologics! Innovent Biologics, a leading biopharmaceutical company specializing in high-quality medicines for #oncology, #autoimmune, #cardiovascular, #metabolic, and #ophthalmologic diseases, has announced promising results from a multicenter, open-label Phase 2 study of #picankibart (R&D code: IBI112), an anti-interleukin 23p19 (IL-23p19) antibody injection, in patients with #plaquepsoriasis who had an inadequate response to previous biologic treatments. The #IL23p19targetedantibody showed significant skin clearance and a favorable safety profile, setting the stage for #Phase3 trials and creating new possibilities for biologic switching in psoriasis care. After 16 weeks of treatment with picankibart, 64.6% of patients (42 out of 65) who previously had inadequate responses—primarily to IL-17 targeting biologics—achieved skin clearance or near-clearance, with a sPGA score of 0 or 1. This study marks the first clinical trial in China to evaluate a switch from other biologics to an IL-23p19-targeted therapy for psoriasis and is expected to provide valuable insights for long-term treatment strategies for patients with moderate to severe psoriasis. #InnoventBiologics #Psoriasis #PsoriasisCare #IL23 #Autoimmunedisease #Targetedantibodytreatment #RASLSSConsulting #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #PortfolioOptimization Detailed News: https://lnkd.in/dA5_vTaD Know more about #RASLSSConsulting: https://lnkd.in/d_daJ5Xv Follow our page for more industry updates: https://lnkd.in/de5zNWmK

🚀 AbbVie to foster scientific expertise in the Middle East and Africa region through CRISP Program! 🚀 AbbVie, a leading global biopharmaceutical company focused on research, recently hosted a visit to its R&D facilities—the AbbVie Cambridge Research Center and Worcester Bioresearch Center—in Boston, USA. The tour offered participants an in-depth look at AbbVie’s #innovativedrugdiscoveryanddevelopment methods, spotlighting key therapeutic areas and the company’s advanced clinical research stages. This event introduced the #CRISP (Clinical Research Advancement Integrated Signature Program), designed to bolster #clinicalresearchcapabilities in the region and align with the shared vision of participating countries to advance research and establish a regional hub for clinical studies, ultimately raising standards of care for patients. AbbVie aims to partner with these countries to enhance healthcare capabilities and create a positive impact for patients. Healthcare leaders, scientists, and experts from #Algeria, #SaudiArabia, and the #UAE attended the visit, gaining exposure to cutting-edge technologies and processes driving AbbVie’s treatments. They participated in engaging discussions on the future of healthcare solutions, as experts at the centers continue to innovate and push scientific boundaries. Additionally, a workshop addressed clinical research challenges and opportunities to advance clinical trials across the Middle East and Africa, emphasizing collaborative efforts to strengthen the regional clinical research landscape. This visit marked the second time AbbVie has welcomed international guests to its R&D centers, offering them a first hand view of the collaborative efforts and advanced technologies that fuel the discovery and development of new molecules. Guests also joined discussions on AbbVie’s pioneering work in #oncology, #immunology, and #neuroscience, which supports the company’s mission to create #innovativemedicines and #solutions that address today’s serious health issues, tackle tomorrow’s medical challenges, and enhance patients’ quality of life. For detailed news: https://lnkd.in/d7Q_Q4y5 Know more about #RASLSSConsulting: https://lnkd.in/d_daJ5Xv Follow our page for more industry updates: https://lnkd.in/de5zNWmK

Taiwan’s Caliway Biopharmaceuticals Completes Final Phase 2b Study of CBL-514, First Injectable for Large-Area Fat Reduction Caliway Biopharmaceuticals concluded the Phase 2b trial of CBL-514 for #nonsurgicalfatreduction (CBL-0205) on October 22, 2024, with topline results expected in Q1 2025. CBL-0205, the second of two Phase 2b studies for CBL-514, was designed in alignment with #USFDA recommendations in preparation for the upcoming Pivotal Phase 3 trial. If both Phase 2b studies meet their endpoints, CBL-514 will become the #firstnonsurgicallipolytictreatment for large areas with Phase 3 trials scheduled for 2025, following efficacy evaluations as recommended by the #FDA. CBL-514 comprises a combination of multiple active pharmaceutical ingredients (APIs), including CBL-A1 and CBL-A2. The CBL-0205 study is a multicenter, single-blinded, randomized, placebo-controlled Phase 2b trial designed to assess the efficacy, safety, and tolerability of CBL-514 compared to its individual APIs, CBL-A1 and CBL-A2, as well as a placebo. Currently, two Phase 2b studies of CBL-514 (CBL-0204 and CBL-0205) are underway for subcutaneous fat reduction, with topline results expected in Q4 2024 and Q1 2025, respectively. These trials were designed to mirror the Phase 3 study by utilizing the same efficacy assessment tools, including #MagneticResonanceImaging (MRI) and the #AbdominalFatReductionScale (AFRS), a U.S. FDA-recommended tool developed by Caliway, to enhance the likelihood of meeting Phase 3 endpoints. Additionally, to reduce potential biases in the single-blinded design, MRI readings and analyses for both Phase 2b trials were reviewed by a blinded Outcomes Assessor from an independent organization before being finalized by the CRO for statistical analysis. #CaliwayBiopharma #CBL514 #fatreduction #largeareafatreduction #firstnonsurgicallipolytictreatment #RASLifeScienceSolutions #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #PortfolioOptimization For detailed news: https://lnkd.in/gZNGyVb7 Know more about #RASLSSConsulting: https://lnkd.in/d_daJ5Xv Follow our page for more industry updates: https://lnkd.in/de5zNWmK

🚀 Big News in UAE’s Life Sciences Ecosystem! 🚀 Mubadala Investment Company’s unit, KELIX bio, has acquired four of #GlobalOneHealthcareHolding’s (#GHH) pharmaceutical assets as part of a strategic push to strengthen the UAE's life sciences infrastructure. This exciting deal includes the #Acquisition of Bioventure , Bioventure Healthcare, Gulf Inject, and Wellpharma Medical Solutions. While the total transaction value remains undisclosed, the move is a significant step towards enhancing the UAE's pharmaceutical industry by addressing prevalent #Diseases, securing #DrugSupply, and reducing #HealthcareCosts. This marks the first acquisition by #KelixBio following its recent purchase by #Mubadala, further demonstrating Mubadala’s commitment to expanding the UAE's life sciences sector. According to Dr. Bakheet Al Katheeri, CEO of UAE Investments at Mubadala, this strategic move aligns with the nation’s ambition to build a knowledge-based economy and foster long-term partnerships. This acquisition also supports government initiatives such as Operation 300bn and Make it in the Emirates, which aim to boost #LocalManufacturing and increase the industrial sector’s contribution to the UAE's GDP. #Mubadala #KelixBio #LifeSciences #Pharmaceuticals #UAE #Operation300bn #MakeItInTheEmirates #HealthcareInnovation #Investments #GHH #RASLifeScienceSolutions #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #PortfolioOptimization Detailed News: https://lnkd.in/dN3_Wa-B Know more about #RASLSSConsulting: https://lnkd.in/d_daJ5Xv Follow our page for more industry updates: https://lnkd.in/de5zNWmK

Great news for those fighting Alzheimer's: Lenovo along with Innovations in Demetia, is set to launch an AI-powered 'Alzheimer's Intelligence' avatar to support early-stage dementia care. This innovative 3D avatar, inspired by the real-life experiences of dementia patients, provides round-the-clock conversational support and personalized guidance. Using AI, it enhances accessibility and compassionate care for individuals diagnosed with dementia and Alzheimer’s. This proof-of-concept project gives people and families navigating a diagnosis of dementia 24-hour access to a conversational avatar that offers curated advice that prioritizes accuracy, privacy, and compassion. Approximately 55 million people are currently living with dementia worldwide, and this number is projected to rise to 139 million by 2050. Upon receiving a dementia diagnosis, individuals often feel overwhelmed and uncertain, with numerous questions about their condition. While this AI doesn’t substitute for human interaction, it serves as a knowledgeable and compassionate source of guidance and reassurance, drawing directly from the experiences and insights of others living with dementia. In this groundbreaking initiative, Lenovo has led the way in utilizing AI through its extensive range of technology solutions, spanning individual to enterprise levels. This advanced technology combines firsthand experiences and insights from hundreds of people living with dementia and Alzheimer’s, creating a responsive, photorealistic 3D avatar capable of engaging in unscripted, natural conversations. With this proof of concept, individuals diagnosed with dementia can access real-time conversational support with just a click. The avatar was developed using a composite of images from 10 individuals living with dementia and Alzheimer’s. Starting with the initial pose of each image, generative AI generated thousands of additional facial expressions and angles based on the subjects. These were then combined into a single dataset and blended with the face of a filmed performer to create "Liv," the AI-powered avatar. The AI is specifically trained and tested for this unique purpose, with the entire project brought to life using Lenovo's devices, services, software, servers, and cloud solutions. This marks the first time that Lenovo’s AI-ready solutions have been combined to create an avatar of this nature. #Alzheimers #DementiaCare #AI #HealthcareInnovation #Lenovo #InnovationsInDementia #BreakthroughTechnology #PatientSupport #CompassionateCare #AIHealthcare #DementiaResearch #RASLSSConsulting #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #PortfolioOptimization For detailed news: https://lnkd.in/d7gB_dba Know more about #RASLSSConsulting: https://lnkd.in/d_daJ5Xv Follow our page for more industry updates: https://lnkd.in/de5zNWmK

🌟 De Novo FDA Approvals in September 2024! 🌟 In September, the FDA approved five groundbreaking #NewDrugs, marking important progress in the #Pharmaceutical industry. These #BreakthroughTherapies bring renewed hope and expanded treatment options for patients worldwide. It’s inspiring to see such advancements shaping the future of healthcare! GE HealthCare Bristol Myers Squibb IntraBio Inc IntraBio Ltd. Zevra Therapeutics Eli Lilly and Company #USFDA #FDAApprovals #Pharmaceuticals #PharmaInnovation #BreakthroughTherapies #PatientCare #Flyrcado #Cobenfy #Aqneursa #Miplyffa #Ebglyss #MyocardialInfarction #Schizophrenia #NiemannPickDisease #AtopicDermatitis #RASLSSConsulting #MarketIntelligence #MarketResearch #MarketEntryStrategy #CompetitiveIntelligence #StrategySupport #PortfolioOptimization Know more about #RASLSSConsulting: https://lnkd.in/d_daJ5Xv Follow our page for more industry updates: https://lnkd.in/de5zNWmK

Tabuk Pharmaceuticals Manufacturing Company, a leading #Saudi pharmaceutical company and a fully-owned subsidiary of Astra Industrial Group, has announced an exclusive #Licensing #Partnership with Hanmi Pharmaceuticals of #SouthKorea. Together, they aim to introduce #Novel, value-added medicines to the Middle East and North Africa (#MENA) region, enhancing #PatientCare and supporting #HealthcareInnovation across the region. Key Highlights of the Agreement: Development & Manufacturing: Hanmi will develop and manufacture the products. Market Authorization & Promotion: Tabuk will handle marketing authorization, registration, importing, and promotion. Expansion & Localization: The agreement includes options for expanding the product range and the potential for tech transfer to enable localized manufacturing at a future stage. This collaboration leverages Hanmi’s #RandD expertise with Tabuk's regional reach, underscoring both companies’ commitment to making high-quality, life-saving treatments more accessible. Ismail Shehada, CEO of Tabuk Pharmaceuticals, shared: “We are thrilled to partner with Hanmi to bring these innovative therapies to the MENA region. This collaboration aligns with our strategic goal to expand access to essential medicines, address critical healthcare needs, and enhance quality of life for patients. Together, we aim to deliver meaningful value to healthcare providers and patients alike.” Ju Hyun Lim, Vice Chairman of Hanmi, added: “We are excited to collaborate with Tabuk Pharmaceuticals to address significant healthcare challenges in the MENA region. This partnership brings together Hanmi’s research expertise and Tabuk’s strong local presence, aiming to make a meaningful difference in the lives of patients across the region.” With healthcare systems in the MENA region facing increasing demands, this partnership showcases a shared commitment to providing value-driven solutions tailored to the region’s needs. Detailed News: https://lnkd.in/dF38ZKvY Know more about #RASLSSConsulting: https://lnkd.in/d_daJ5Xv Follow our page for more industry updates: https://lnkd.in/de5zNWmK #TabukPharmaceuticals #HanmiPharmaceutical #MENA #SaudiArabia #Healthcare #PharmaPartnership #LifeChangingTreatments #InnovationInHealthcare #PatientOutcomes #StrategicCollaboration #HealthInnovation #RASLSS #MarketIntelligence #MarketResearch #MarketEntryStrategy #CompetitiveIntelligence #StrategySupport #PortfolioOptimization

Highlights from Day 2 and 3 at #CPHIMilan Know more about #RASLSSConsulting: https://shorturl.at/62Jhq #RASLSSConsulting #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #PortfolioOptimization #ConferenceCoverage